These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32674911)

  • 1. Sirolimus for seizure control in children with Tuberous sclerosis: Is it really a wonder drug?
    Panda PK; Sharawat IK
    Seizure; 2020 Oct; 81():338-339. PubMed ID: 32674911
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to the letter "Sirolimus for seizure control in children with tuberous sclerosis: Is it really a wonder drug(SEIZURE-D-20-00436)?".
    He W; Wang YY; Zou LP
    Seizure; 2020 Oct; 81():340-341. PubMed ID: 32713657
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapamycin reduces seizure frequency in tuberous sclerosis complex.
    Muncy J; Butler IJ; Koenig MK
    J Child Neurol; 2009 Apr; 24(4):477. PubMed ID: 19151365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early therapy with sirolimus reduces size of a large solid renal mass but not seizure activity in an infant with tuberous sclerosis.
    Hani SB; Artunduaga M; Ludwig K; Bissler JJ; Wolf MTF
    J Nephrol; 2024 Jan; 37(1):203-205. PubMed ID: 37768546
    [No Abstract]   [Full Text] [Related]  

  • 5. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?
    Wiegand G; May TW; Ostertag P; Boor R; Stephani U; Franz DN
    Eur J Paediatr Neurol; 2013 Nov; 17(6):631-8. PubMed ID: 23845174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor.
    Siroky BJ; Towbin AJ; Trout AT; Schäfer H; Thamann AR; Agricola KD; Tudor C; Capal J; Dixon BP; Krueger DA; Franz DN
    J Pediatr; 2017 Aug; 187():318-322.e2. PubMed ID: 28600153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus treatment for tuberous sclerosis complex prior to epilepsy: Evidence from a registry-based real-world study.
    Shen YW; Wang YY; Zhang MN; Xu Y; Lu Q; He W; Chen HM; Liu LY; Pang LY; Wang QH; Dun S; Li YF; Gao J; Han F; Zou LP
    Seizure; 2022 Apr; 97():23-31. PubMed ID: 35286974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial.
    Overwater IE; Rietman AB; Bindels-de Heus K; Looman CW; Rizopoulos D; Sibindi TM; Cherian PJ; Jansen FE; Moll HA; Elgersma Y; de Wit MC
    Neurology; 2016 Sep; 87(10):1011-8. PubMed ID: 27511181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis.
    Paul E; Thiele E
    N Engl J Med; 2008 Jan; 358(2):190-2. PubMed ID: 18184966
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.
    Davies DM; Johnson SR; Tattersfield AE; Kingswood JC; Cox JA; McCartney DL; Doyle T; Elmslie F; Saggar A; de Vries PJ; Sampson JR
    N Engl J Med; 2008 Jan; 358(2):200-3. PubMed ID: 18184971
    [No Abstract]   [Full Text] [Related]  

  • 12. Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: A prospective cohort study.
    He W; Chen J; Wang YY; Zhang MN; Qian-Lu ; Wang QH; Luo XM; Chen XQ; Zou LP
    Seizure; 2020 Jul; 79():20-26. PubMed ID: 32416565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Use-Long-term Follow-up of First Tuberous Sclerosis Complex Patient Treated De Novo With Sirolimus After Kidney Transplantation: A Case Report.
    Tarasewicz A; Dębska-Ślizień A; Rutkowska B; Szurowska E; Matuszewski M
    Transplant Proc; 2018; 50(6):1904-1909. PubMed ID: 30056926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].
    Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S
    Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma.
    Salido R; Garnacho-Saucedo G; Cuevas-Asencio I; Ruano J; Galán-Gutierrez M; Vélez A; Moreno-Giménez JC
    J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1315-8. PubMed ID: 21834948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin.
    Kaufman McNamara E; Curtis AR; Fleischer AB
    J Dermatolog Treat; 2012 Feb; 23(1):46-8. PubMed ID: 20673154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
    Dill PE; De Bernardis G; Weber P; Lösch U
    Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary care management of tuberous sclerosis complex in children.
    Manohara D
    J Am Acad Nurse Pract; 2012 Jul; 24(7):391-9. PubMed ID: 22735062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberous sclerosis complex as a model disease for developing new therapeutics for epilepsy.
    Jeong A; Wong M
    Expert Rev Neurother; 2016; 16(4):437-47. PubMed ID: 26854692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Topical sirolimus 0.4% formulation for treatment of facial angiofibromas].
    Cuevas Asencio I; Albornoz López R; Salido Vallejo R; Reyes Malia M
    Farm Hosp; 2012; 36(5):433-4. PubMed ID: 22858090
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.